TW202317523A - 結直腸癌治療的生物標記 - Google Patents

結直腸癌治療的生物標記 Download PDF

Info

Publication number
TW202317523A
TW202317523A TW111126187A TW111126187A TW202317523A TW 202317523 A TW202317523 A TW 202317523A TW 111126187 A TW111126187 A TW 111126187A TW 111126187 A TW111126187 A TW 111126187A TW 202317523 A TW202317523 A TW 202317523A
Authority
TW
Taiwan
Prior art keywords
drug
abnormalities
drug sensitivity
individual
drug resistance
Prior art date
Application number
TW111126187A
Other languages
English (en)
Chinese (zh)
Inventor
袁鵬飛
金鳴
張永建
申紅豔
楊玲
劉娜
蘇美華
鄭雅茹
李玉蘭
Original Assignee
大陸商北京輯因醫療科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京輯因醫療科技有限公司 filed Critical 大陸商北京輯因醫療科技有限公司
Publication of TW202317523A publication Critical patent/TW202317523A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111126187A 2021-07-12 2022-07-12 結直腸癌治療的生物標記 TW202317523A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/105822 2021-07-12
WOPCT/CN2021/105816 2021-07-12
CN2021105822 2021-07-12
CN2021105816 2021-07-12

Publications (1)

Publication Number Publication Date
TW202317523A true TW202317523A (zh) 2023-05-01

Family

ID=84919026

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111126186A TW202309299A (zh) 2021-07-12 2022-07-12 鑒定癌細胞中藥物敏感基因和耐藥基因的方法
TW111126187A TW202317523A (zh) 2021-07-12 2022-07-12 結直腸癌治療的生物標記

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW111126186A TW202309299A (zh) 2021-07-12 2022-07-12 鑒定癌細胞中藥物敏感基因和耐藥基因的方法

Country Status (2)

Country Link
TW (2) TW202309299A (fr)
WO (2) WO2023284736A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117210568B (zh) * 2023-10-30 2024-06-21 云南省肿瘤医院(昆明医科大学第三附属医院) 一种检测家族遗传性结直肠癌的snp标志物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543353A1 (fr) * 2013-09-23 2019-09-25 The University of Chicago Procédés et compositions concernant une thérapie anticancéreuse au moyen d'agents endommageant l'adn
WO2015100257A1 (fr) * 2013-12-23 2015-07-02 The General Hospital Corporation Procédés et dosages pour la détermination d'une fonction de voie brca1 réduite dans une cellule cancéreuse
WO2017059357A1 (fr) * 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
JOP20190197A1 (ar) * 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2019133697A1 (fr) * 2017-12-27 2019-07-04 Tesaro, Inc. Méthodes de traitement du cancer
AU2018397736A1 (en) * 2017-12-29 2020-07-09 Vertex Pharmaceuticals Incorporated Methods of cancer treatment using an ATR inhibitor
CN110343724B (zh) * 2018-04-02 2021-10-12 北京大学 用于筛选和鉴定功能性lncRNA的方法
CN111334531A (zh) * 2018-12-18 2020-06-26 博雅辑因（北京）生物科技有限公司 高信噪比阴性遗传筛选方法
WO2020125762A1 (fr) * 2018-12-20 2020-06-25 Peking University Compositions et procédés de criblage génétique hautement efficace utilisant des constructions d'arn guide à code-barres
CN111349654B (zh) * 2018-12-20 2023-01-24 北京大学 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
CN110570922B (zh) * 2019-07-19 2022-06-10 浙江大学 一种评估hr缺陷模型及应用
WO2021086107A1 (fr) * 2019-10-30 2021-05-06 (재)록원바이오융합연구재단 Procédé de détermination de la réactivité à un inhibiteur de parp
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用

Also Published As

Publication number Publication date
WO2023284735A1 (fr) 2023-01-19
TW202309299A (zh) 2023-03-01
WO2023284736A1 (fr) 2023-01-19

Similar Documents

Publication Publication Date Title
US20220010385A1 (en) Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US11174519B2 (en) Method of treating cancer
AU2020223754B2 (en) Methods and materials for assessing loss of heterozygosity
US20150301058A1 (en) Biomarker compositions and methods
US11810672B2 (en) Cancer score for assessment and response prediction from biological fluids
US20200185054A1 (en) Device and method of identifying and evaluating a tumor progression
WO2023109875A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
IL297812A (en) Immunotherapy response signature
US20230113092A1 (en) Panomic genomic prevalence score
JP2021528094A (ja) マイクロサテライト不安定性の検出
JP2021526375A (ja) 検出方法
IL301304A (en) predicts metastases
US10610521B2 (en) Biomarkers for response to rapamycin analogs
WO2023284736A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
US20230416829A1 (en) Immunotherapy Response Signature
TW201843306A (zh) 腫瘤與配對的正常cfRNA
WO2023109876A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
WO2023125788A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
WO2023125787A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
IL303726A (en) Treatment response signatures
Tirtei Tumour Genomic Profile Analysis in Children, Adolescents and Young Adults With Bone Sarcomas: a national multi-centre prospective trial
EP3665307B1 (fr) Matières et méthodes de stratification et de traitement de cancers
Roura Canalda A multi-omics evaluation of somatic mutations, transcriptomic dysregulation, chromatin accessibility and remodeling in High-Grade Gliomas: PhD thesis
Wu Circulating cell-free DNA methylation analysis of metastatic prostate cancer
WO2023152664A1 (fr) Plate-forme analytique utilisant un réseau d'interaction de gènes associé à npm1 pour identifier des traits génétiques